PFG Advisors Has $934,000 Stock Position in IQVIA Holdings Inc. $IQV

PFG Advisors decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 51.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,144 shares of the medical research company’s stock after selling 4,310 shares during the period. PFG Advisors’ holdings in IQVIA were worth $934,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of IQV. Silphium Asset Management Ltd bought a new position in IQVIA in the fourth quarter worth $1,627,000. Smith Salley Wealth Management lifted its position in IQVIA by 1.0% in the fourth quarter. Smith Salley Wealth Management now owns 12,916 shares of the medical research company’s stock worth $2,911,000 after purchasing an additional 132 shares during the period. TD Waterhouse Canada Inc. lifted its position in IQVIA by 72.8% in the fourth quarter. TD Waterhouse Canada Inc. now owns 356 shares of the medical research company’s stock worth $80,000 after purchasing an additional 150 shares during the period. Revisor Wealth Management LLC bought a new position in IQVIA in the fourth quarter worth $345,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in IQVIA by 6.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 127,668 shares of the medical research company’s stock worth $28,778,000 after purchasing an additional 7,578 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $160.70 on Friday. The stock has a 50-day simple moving average of $170.12 and a 200 day simple moving average of $203.01. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The stock has a market capitalization of $27.27 billion, a price-to-earnings ratio of 20.45, a P/E/G ratio of 1.74 and a beta of 1.39.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. During the same period in the previous year, the business posted $3.12 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 11.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on IQV. Stifel Nicolaus reduced their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. UBS Group reduced their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. Royal Bank Of Canada began coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price for the company. Finally, Evercore reaffirmed an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $226.63.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.